Stefania Erra

Stefania Erra

Auto-generated profile, based on publicly available information

Stefania Erra

Pathology Unit, ASL AL, 15033 Casale Monferrato, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
GSGermano Savastano
Germano Savastano
LPLucio Palombini
Lucio Palombini
VMVincenzo Muscariello
Vincenzo Muscariello
SEStefania Erra
Stefania Erra

1 April 2011
Verified
Journal Article
Closed access
SES Erra
S Erra
DCD Costamagna
D Costamagna

Verified
Journal Article
Open access
PDF file
FMFederica Zito Marino
Federica Zito Marino
Carminia Maria Della CorteCarminia Maria Della Corte
Carminia Maria Della Corte
VCVincenza Ciaramella
Vincenza Ciaramella
SEStefania Erra
Stefania Erra
ARandrea ronchi
andrea ronchi
MAMarina Accardo
Marina Accardo
Malignant pleural mesothelioma (MPM) is a highly lethal malignancy that unfortunately cannot benefit from molecularly targeted therapies. Although previous results showed the pivotal role of various receptor tyrosine kinases (RTKs) in MPM tumorigenesis, the treatment with a single inhibitor targeting one specific RTK has been shown to be ineffective in MPM patients. The main aim of the present study was to investigate the potential role of AXL and MET receptors in MPM and the possible efficacy of treatment with AXL and MET multitarget inhibitors. Immunohistochemical and FISH analyses were performed in a wide series of formalin-fixed paraffin-embedded MPM samples to detect the expression of two receptors and the potential gene amplification. In vitro studies were performed to evaluate putative correlations between the target’s expression and the cell sensitivity to AXL-MET multitarget inhibitors. In our series, 10.4% of cases showed a co-expression of AXL and MET, regardless of their ligand expression, and the gene amplification. Furthermore, our in vitro results suggest that the concomitant pharmacological inhibition of AXL and MET may affect the proliferative and aggressiveness of MPM cells. In conclusion, the subset of MPM patients with AXL-MET co-activation could benefit from treatment with specific multitarget inhibitors.

12 August 2008
Verified
Journal Article
Closed access
DCDaniela Costamagna
Daniela Costamagna
SEStefania Erra
Stefania Erra
AZAntonio Zullo
Antonio Zullo
GSGiovanni Servente
Giovanni Servente
RDRiccardo Durando
Riccardo Durando

24 February 2012
Verified
Journal Article
Closed access
SES Erra
S Erra
DCD Costamagna
D Costamagna

1 January 2018 in Archives of Clinical and Biomedical Research
Verified
Journal Article
Open access
SEStefania Erra
Stefania Erra
AFAlessia Frigeri
Alessia Frigeri
APAlessia Picozzi
Alessia Picozzi
Placental Mesenchymal Dysplasia: Report of A Case and Review of the Literature, Archives of Clinical and Biomedical Research